Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.

Both concentrations of triamcinolone acetonide are equally effective and safe for treating patchy alopecia areata.

Mesalazine showed limited effectiveness in treating children with severe alopecia areata.

Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.

CD28 is a promising target for treating alopecia areata with belatacept.

CD28 is a promising target for treating alopecia areata with belatacept.

Baricitinib slightly increased cholesterol levels in alopecia areata patients, but these changes were manageable.

Upadacitinib is effective and safe for treating severe alopecia areata in teens.

Infliximab can cause SAPHO syndrome, which may improve with Spesolimab and methotrexate.

Baricitinib was effective in treating severe and very severe alopecia areata after 52 weeks.

Baricitinib is effective and safe for treating severe alopecia areata for up to 5 years.

Baricitinib is effective for treating severe alopecia areata in Japanese patients, but long-term safety needs more study.

Most patients with rheumatoid arthritis continued methotrexate treatment over two years, but those who stopped and restarted experienced more side effects and less improvement.

A woman with skin eruptions and hair loss improved significantly with ointment treatment.

Calprotectin levels are higher in alopecia areata patients, indicating systemic inflammation.

Methotrexate treatment for rheumatoid arthritis has a serious infection rate of about two per 100 patient-years.

Mesenchymal stem cells and their secretions might help treat chronic skin inflammation in atopic dermatitis.

JAK inhibitors can effectively reverse hair loss in people with alopecia areata.

Experts created guidelines for who in Australia can get subsidized JAK inhibitor therapy for alopecia areata.

Intralesional triamcinolone is more effective than cryotherapy for treating alopecia areata in middle-aged adults.

Oral tofacitinib may be an effective and tolerable treatment for some people with severe alopecia areata.

Tofacitinib and baricitinib are similarly effective and safe for alopecia areata, but baricitinib works faster.

Squaric acid dibutylester can cause severe skin reactions in people with allergies.

DNCB is highly effective for treating alopecia areata with minimal long-term side effects.

JAK inhibitors can be safely used in alopecia areata patients with latent hepatitis B or tuberculosis, with proper monitoring.

Certain immune cells in atopic dermatitis skin could be targeted for treatment.

Antihistamines may help with hair regrowth in alopecia areata, but dupilumab's effects are mixed.

Tofacitinib effectively promotes hair regrowth in alopecia areata with minimal side effects.

Brodalumab is more effective than ustekinumab in treating psoriasis.

Combining triamcinolone acetonide and immunotherapy can help regrow hair in some alopecia totalis patients.